ICCM — Icecure Medical Share News
0.000.00%
Last trade - 00:00- $3.56m
- -$8.47m
- $3.38m
Brief: Icecure's Prosense Deepens Regulatory Approval In India
Brief: Icecure System Successfully Treated Kidney Cancer Tumor With 92% Disease-Free Survival Rate And 100% Secondary Local Control Rate
Brief: Icecure Medical Files Appeal With U.S. FDA Requesting A Review Of Its De Novo Classification For Prosense® In Early-Stage Breast Cancer
US-listed healthcare stocks fall amid Middle East conflict
US-listed healthcare firms down amid Middle East conflict
U.S. STOCKS ON THE MOVE-Gold miners, Goosehead Insurance, FedEx
U.S. STOCKS ON THE MOVE-Lululemon, Copper miners, Gold miners
U.S. STOCKS ON THE MOVE-Exscientia, Fresh Track Therapeutics, Pinterest
IceCure falls as FDA denies de novo request for breast cancer treatment system
Brief: Icecure Medical Receives FDA Response To De Novo Classification Request For Breast Cancer Study
Brief: Icecure Medical Takes Initiative As It Prepares To Accelerate The Commercialization Of Prosense In U.S. And Canada Appoints VP Of Sales, North America
Brief: Icecure Medical Reports First Half 2023 Results
IceCure Medical rises as tumor removal device gets patent in Japan
U.S. STOCKS ON THE MOVE-Tesla, Athenex Inc, Entrada Therapeutics
Icecure Medical soars on positive results in kidney tumors therapy trial
U.S. STOCKS ON THE MOVE-Tesla, Netflix, Entrada Therapeutics, Gilead Sciences
NASDAQ RESUMED AT 09:04 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:52 PM